40 terminated. 40 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 40 | Terminated 40 |
| Phase 1 | 4 | Terminated 4 |
| Phase 3 | 1 | Terminated 1 |
Follow Hepatitis B: new trials by email Literature Review of Hepatitis B trials Research Report on Hepatitis B
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV Selgantolimod, Placebo - Hepatitis B, HIV Infections | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 29 | 2023-05-01 | 2026-11-17 |
| Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B STSG-0002 Injection - Chronic Hepatitis b | Phase 2 | Terminated | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 9 | 2023-04-25 | 2023-12-19 |
| To Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B STSG-0002 Injection - Chronic Hepatitis b | Phase 2 | Terminated | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 9 | 2023-04-25 | 2023-12-19 |
| Treatment of Patients With Chronic Hepatitis B With Hepatitis B Immunoglobulins Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®) - Chronic Hepatitis B | Phase 2 | Terminated | Hannover Medical School | 13 | 2022-08-15 | 2025-09-04 |
| Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection GSK3965193, Placebo to match GSK3965193, Bepirovirsen - Hepatitis B | Phase 1 / Phase 2 | Terminated | GlaxoSmithKline | 74 | 2022-04-14 | 2026-10-14 |
| A Study of Safety and Efficacy of ATI-2173 and Vebicorvir in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection ATI-2173 25mg, Vebicorvir 300mg, Viread 300Mg Tablet - Chronic Hepatitis b | Phase 2 | Terminated | Antios Therapeutics, Inc | 2 | 2022-04-11 | 2022-05-31 |
| A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection JNJ-73763989, PegIFN-alpha-2a, Tenofovir disoproxil - Hepatitis B, Chronic | Phase 2 | Terminated | Janssen Research & Development, LLC | 1 | 2021-11-03 | 2024-03-06 |
| A Study to Evaluate the Antiviral Activity and Safety of HH-003 Injection in Subjects With Chronic Hepatitis B and Hepatitis D Co-infection HH-003 20mg/kg, HH-003 3mg/kg - Chronic Hepatitis B and Hepatitis D Co-infection | Phase 2 | Terminated | Huahui Health | 9 | 2021-08-11 | 2023-10-10 |
| A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection VBR, AB-729, SOC NrtI - Chronic Hepatitis B | Phase 2 | Terminated | Assembly Biosciences | 65 | 2021-05-07 | 2023-11-14 |
| A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection ATI-2173, Viread, AB-729 - Hepatitis B, Chronic, Hepatitis D | Phase 2 | Terminated | Antios Therapeutics, Inc | 40 | 2021-03-30 | 2022-11-18 |
| A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection ABI-H0731, ETV, Peg-IFNα - Chronic Hepatitis B | Phase 2 | Terminated | Assembly Biosciences | 54 | 2021-02-18 | 2023-10-06 |
| HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB) HepTcell, Placebo - Hepatitis B, Chronic | Phase 2 | Terminated | Altimmune, Inc. | 87 | 2020-12-26 | 2025-12-08 |
| A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors ABI-H0731, Placebo, NrtI - Chronic Hepatitis B | Phase 2 | Terminated | Assembly Biosciences | 2 | 2020-11-11 | 2022-10-20 |
| Evaluation HEC121120 Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study HEC121120 tablets, HEC121120 placebo tablets, entecavir tablets - Hepatitis B, Chronic | Phase 1 / Phase 2 | Terminated | Sunshine Lake Pharma Co., Ltd. | 52 | 2020-10-09 | 2024-06-24 |
| A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection ABI-H2158, Placebo, Entecavir (ETV) - Chronic Hepatitis B | Phase 2 | Terminated | Assembly Biosciences | 88 | 2020-08-28 | 2022-09-15 |
| Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD) EYP001a, Placebo, Nucleotide analogue (Entecavir or Tenofovir Disoproxil) - Hepatitis B, Chronic | Phase 2 | Terminated | Enyo Pharma | 26 | 2020-05-12 | 2022-11-02 |
| Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus Inarigivir soproxil, Tenofovir alafenamide fumarate (TAF) - Hepatitis B, HBV | Phase 2 | Terminated | F-star Therapeutics, Inc. | 5 | 2019-10-10 | 2020-07-21 |
| Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor Inarigivir soproxil, Nucleoside/nucleotide (NUC) analogue inhibitors - Hepatitis B, HBV | Phase 2 | Terminated | F-star Therapeutics, Inc. | 64 | 2019-06-18 | 2020-07-22 |
| Evaluating the Effects of Inarigivir on Immune Response and Viral Markers in Chronic Hepatitis B Patients inarigivir soproxil - HBV, Hepatitis B | Phase 2 | Terminated | F-star Therapeutics, Inc. | 8 | 2019-04-11 | 2020-04-29 |
| A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis Ambrisentan - Cirrhosis, Portal Hypertension | Phase 2 | Terminated | Noorik Biopharmaceuticals AG | 19 | 2019-04-11 | 2021-02-26 |
Showing 20 of 40. Sign in to see all of them.
Hepatitis B, Chronic (26) · Hepatitis (2) · Hepatitis C (2) · Hepatitis D (2) · Ascites (1) · Bronchiolitis Obliterans Syndrome (1) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Diphtheria (1) · Esophageal and Gastric Varices (1) · Fibrosis (1) · HIV Infections (1) · Haemophilus Infections (1) · Hypertension, Portal (1)
Blood-Borne Infections (40) · Communicable Diseases (40) · DNA Virus Infections (40) · Digestive System Diseases (40) · Hepadnaviridae Infections (40) · Hepatitis, Viral, Human (40) · Infections (40) · Liver Diseases (40) · Virus Diseases (40) · Hepatitis (38) · Pathologic Processes (28) · Pathological Conditions, Signs and Symptoms (28) · Disease Attributes (27) · Chronic Disease (26) · Hepatitis, Chronic (26)
Tenofovir (12) · entecavir (12) · ARC-520 (6) · Histamine Antagonists (4) · tenofovir alafenamide (4) · clevudine (3) · hepatitis B hyperimmune globulin (2) · peginterferon alfa-2a (2) · Chlorpheniramine (1) · Diphenhydramine (1) · Dosage Forms (1) · Emtricitabine (1) · Hepatitis B Vaccines (1) · Nucleobindins (1) · Nucleosides (1)
Arrowhead Pharmaceuticals (6) · Assembly Biosciences (5) · Bukwang Pharmaceutical (3) · F-star Therapeutics, Inc. (3) · GlaxoSmithKline (3) · Antios Therapeutics, Inc (2) · Staidson (Beijing) Biopharmaceuticals Co., Ltd (2) · Alexion Pharmaceuticals, Inc. (1) · Altimmune, Inc. (1) · Bausch Health Americas, Inc. (1) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Dynavax Technologies Corporation (1) · Eisai Limited (1) · Enyo Pharma (1) · Gilead Sciences (1)
China (12) · South Korea (11) · United States (10) · Canada (9) · Hong Kong (9) · Germany (7) · United Kingdom (7) · New Zealand (6) · Spain (5) · Taiwan (5) · Thailand (5) · Australia (4) · Poland (4) · France (3) · Moldova (3)
Hyo Suk Lee, M.D., Ph.D. (3) · Don Mitchell (2) · Guiqiang Wang (2) · Bruce Given, MD (1)
PMID 16628625, PMID 24995515, PMID 33712437, PMID 34029994, PMID 38510983
2014 (3), 2015 (1), 2017 (1), 2018 (1), 2019 (1), 2023 (1)